These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32930951)

  • 1. Current Regulation for Bioequivalence Evaluations of Generic Ophthalmic Dosage Forms in Japan.
    Myoenzono A; Kuribayashi R; Yamaguchi T; Ogawa T; Takagi K
    Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):697-702. PubMed ID: 32930951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generic Drug Product Development in Japan: Regulatory Updates During 2014-2019 and the Future.
    Kasuga M; Kuribayashi R; Ogawa T; Ugi A; Yamaguchi T; Takagi K; Hirota M
    Eur J Drug Metab Pharmacokinet; 2021 Nov; 46(6):711-719. PubMed ID: 34586614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union.
    Kuribayashi R; Yamaguchi T; Sako H; Takishita T; Takagi K
    Clin Pharmacokinet; 2017 Mar; 56(3):225-233. PubMed ID: 27461251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modernization and Strengthening of Bioequivalence Guidelines in Japan.
    Kuribayashi R; Yamaguchi T; Takagi K
    Clin Pharmacokinet; 2021 Feb; 60(2):145-151. PubMed ID: 33247363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First approval of generic dry powder inhaler drug products in Japan.
    Kuribayashi R; Myoenzono A
    Drug Deliv Transl Res; 2020 Oct; 10(5):1517-1519. PubMed ID: 32613551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory Considerations of Bioequivalence Studies for Oral Solid Dosage Forms in Japan.
    Kuribayashi R; Takishita T; Mikami K
    J Pharm Sci; 2016 Aug; 105(8):2270-7. PubMed ID: 27372551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Understanding of the Equivalence Evaluations for In Vitro Tests on Generic Dry Powder Inhaler Drug Products in Japan.
    Kuribayashi R; Myoenzono A; Takagi K; Hirota M
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):743-745. PubMed ID: 31062276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First Approval of Generic Mometasone Furoate Nasal Suspension Spray in Japan: Similarities and Differences Between Japan and the USA.
    Kuribayashi R; Kasuga M; Kuwana K; Yamaguchi T
    Ther Innov Regul Sci; 2023 Mar; 57(2):173-177. PubMed ID: 36100793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Trends in the quality evaluation of generic products and bioequivalence guidelines].
    Yomota C
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2012; (130):1-12. PubMed ID: 23243982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Generic Drug Reviews for Marketing Authorization between Japan and Canada.
    Kuribayashi R; Appleton S
    Drugs R D; 2017 Sep; 17(3):371-379. PubMed ID: 28577294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in in-vitro bioequivalence testing methods for complex ophthalmic generic products.
    Renukuntla J; Palakurthi SS; Bolla PK; Clark BA; Boddu SHS; Manda P; Sockwell S; Charbe NB; Palakurthi S
    Int J Pharm; 2022 Nov; 627():122209. PubMed ID: 36162609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of Generic Drugs in Japan: the Current Situation and Future Prospects.
    Kuribayashi R; Matsuhama M; Mikami K
    AAPS J; 2015 Sep; 17(5):1312-6. PubMed ID: 25943503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, Pharmacokinetic, and In Vitro Studies to Support Bioequivalence of Ophthalmic Drug Products.
    Choi SH; Lionberger RA
    AAPS J; 2016 Jul; 18(4):1032-8. PubMed ID: 27184578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Survey of the Regulatory Requirements for the Waiver of In Vivo Bioequivalence Studies of Generic Products in Certain Dosage Forms by Participating Regulators and Organisations of the International Pharmaceutical Regulators Programme.
    Garcia Arieta A; Simon C; Tam A; Mendes Lima Santos G; Freitas Fernandes EA; Rodríguez Martínez Z; Rodrigues C; Park SA; Kim J; Kim K; Kuribayashi R; Myoenzono A; Shimojo K; Walther C; Roost MS; Hung WY; Hsu LF; Crane C; Braddy AC; Van Oudtshoorn J; Gutierrez Triana DA; Guzmán Aurela E; Jones B; Potthast H; Abalos I
    J Pharm Pharm Sci; 2021; 24():113-126. PubMed ID: 33734975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of generic ophthalmic drugs.
    Novack GD
    Ocul Surf; 2013 Jan; 11(1):54-6. PubMed ID: 23321360
    [No Abstract]   [Full Text] [Related]  

  • 16. A generic drug primer: regulatory aspects and scientific concepts.
    Henderson JD; White GL
    Mil Med; 1998 Apr; 163(4):193-7. PubMed ID: 9575760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generating Model Integrated Evidence for Generic Drug Development and Assessment.
    Zhao L; Kim MJ; Zhang L; Lionberger R
    Clin Pharmacol Ther; 2019 Feb; 105(2):338-349. PubMed ID: 30414386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissolution Profiles of Generic Products in Dissolution Media Defined by Japanese Guidelines for Bioequivalence Studies.
    Kajiwara E; Kamizato H; Shikano M
    Ther Innov Regul Sci; 2021 Sep; 55(5):1096-1100. PubMed ID: 34097289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Dissolution Similarity Assessment Methods for Products with Large Variations: f
    Yoshida H; Shibata H; Izutsu KI; Goda Y
    Biol Pharm Bull; 2017; 40(5):722-725. PubMed ID: 28458360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Update of the Brazilian Regulatory Bioequivalence Recommendations for Approval of Generic Topical Dermatological Drug Products.
    Soares KC; Santos GM; Gelfuso GM; Gratieri T
    AAPS J; 2015 Nov; 17(6):1517-8. PubMed ID: 26122498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.